Aoki Tomoko, Nishida Naoshi, Kurebayashi Yutaka, Sakai Kazuko, Fujiwara Naoto, Tsurusaki Masakatsu, Hanaoka Kohei, Morita Masahiro, Chishina Hirokazu, Takita Masahiro, Hagiwara Satoru, Ida Hiroshi, Ueshima Kazuomi, Minami Yasunori, Takebe Atsushi, Murase Takaaki, Kamei Keiko, Nakai Takuya, Matsumoto Ippei, Nishio Kazuto, Kudo Masatoshi
Department of Gastroenterology and Hepatology/Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
Department of Pathology, Keio University School of Medicine, Tokyo, Japan.
Clin Mol Hepatol. 2025 Mar 11. doi: 10.3350/cmh.2024.1088.
BACKGROUND/AIMS: Previously, we advocated the importance of classifying hepatocellular carcinoma (HCC) based on physiological functions. This study aims to classify HCC by focusing on liver-intrinsic metabolism and glycolytic pathway in cancer cells.
Comprehensive RNA/DNA sequencing, immunohistochemistry, and radiological evaluations were performed on HCC tissues from the training cohort (n=136) and validated in 916 public samples. HCC was classified using hierarchical clustering and compared with previous molecular, histopathological, and hemodynamic classifications.
Liver-specific metabolism and glycolysis are mutually exclusive and were divided into two major subclasses: The "rich metabolism" subclass (60.3%) is characterized by enhanced bile acid and fatty acid metabolism, well-to-moderate differentiation, microtrabecular or pseudoglandular pattern, and homogeneous arterial-phase hyperenhancement (APHE), corresponding to Hoshida S3 with favorable prognosis. In IL6-JAK-STAT3-high (25.0%) conditions, upregulated ALB expression, enhanced gluconeogenesis and urea cycle activity, and an inflammatory-microenvironment are observed. Conversely, the Wnt/β-catenin-high environment (19.9%) features elevated GLUL, APOB and CYP3A4 expression, frequent CTNNB1 (D32-S37) mutations, and an immune-desert/excluded phenotype. The "glycolysis" subclass (39.7%), characterized by histopathological dedifferentiation and downregulated liver-specific metabolism, encompasses subclasses with PI3K/mTOR (20.6%) and NOTCH/TGF-β (19.1%) signaling. These often exhibit TP53 mutations, macrotrabecular massive or compact patterns, inhomogeneous/rim-APHE, and high expression of hypoxia-inducible factors and glucose transporters, corresponding to Hoshida S1/2 with poor prognosis.
The loss of liver-specific metabolism correlates with morphological dedifferentiation, indicating cellular dedifferentiation may exhibit both physiological and pathological duality. Key signaling pathways involved in the maturation process from fetal to adult liver and zonation program may play a critical role in defining HCC diversity.
背景/目的:此前,我们主张基于生理功能对肝细胞癌(HCC)进行分类的重要性。本研究旨在通过关注癌细胞中肝脏固有代谢和糖酵解途径对HCC进行分类。
对来自训练队列(n = 136)的HCC组织进行了全面的RNA/DNA测序、免疫组织化学和放射学评估,并在916个公共样本中进行了验证。使用层次聚类对HCC进行分类,并与先前的分子、组织病理学和血流动力学分类进行比较。
肝脏特异性代谢和糖酵解相互排斥,分为两个主要亚类:“丰富代谢”亚类(60.3%)的特征是胆汁酸和脂肪酸代谢增强、分化良好至中等、微小梁或假腺泡模式以及均匀的动脉期高增强(APHE),对应于预后良好的Hoshida S3。在IL6-JAK-STAT3高表达(25.0%)的情况下,观察到ALB表达上调、糖异生和尿素循环活性增强以及炎症微环境。相反,Wnt/β-连环蛋白高表达环境(19.9%)的特征是GLUL、APOB和CYP3A4表达升高、频繁的CTNNB1(D32-S37)突变以及免疫荒漠/排除表型。“糖酵解”亚类(39.7%)的特征是组织病理学去分化和肝脏特异性代谢下调,包括PI3K/mTOR(20.6%)和NOTCH/TGF-β(19.1%)信号传导的亚类。这些通常表现出TP53突变、大的小梁状大块或致密模式、不均匀/边缘APHE以及缺氧诱导因子和葡萄糖转运蛋白的高表达,对应于预后不良的Hoshida S1/2。
肝脏特异性代谢的丧失与形态学去分化相关,表明细胞去分化可能表现出生理和病理双重性。从胎儿肝脏到成人肝脏的成熟过程以及区域化程序中涉及的关键信号通路可能在定义HCC多样性方面发挥关键作用。